India Clears GSK For ‘Quick' Trials Of H1N1 Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
India has given its okay for multinational drug maker GlaxoSmithKline to streamline usual procedures and conduct quick trials of an H1N1 flu vaccine in India. The move is expected to make the GSK vaccine available in India by the end of the year, probably as early as December. India's health ministry has ordered 10 million doses of the vaccine if the trials prove successful, a move that encouraged GSK to test the vaccine in the country. The government plans to conduct its own trials simultaneously with GSK's. (Click here for more
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.